21.27
0.80 (3.91%)
| Previous Close | 20.47 |
| Open | 20.50 |
| Volume | 584,567 |
| Avg. Volume (3M) | 1,211,235 |
| Market Cap | 1,862,775,552 |
| Price / Earnings (Forward) | 4.65 |
| Price / Sales | 230.45 |
| Price / Book | 1.63 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Operating Margin (TTM) | -2,059.11% |
| Diluted EPS (TTM) | -3.49 |
| Quarterly Revenue Growth (YOY) | 78.50% |
| Total Debt/Equity (MRQ) | 1.81% |
| Current Ratio (MRQ) | 14.97 |
| Operating Cash Flow (TTM) | -247.58 M |
| Levered Free Cash Flow (TTM) | -155.09 M |
| Return on Assets (TTM) | -23.05% |
| Return on Equity (TTM) | -32.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | IDEAYA Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 3.13 |
|
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.04% |
| % Held by Institutions | 109.57% |
| 52 Weeks Range | ||
| Median | 50.00 (135.07%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 14 Feb 2025 | 50.00 (135.07%) | Buy | 21.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |